Publications
Found 1 results
Filters: Author is X.B. Song [Clear All Filters]
“Effect of IL-18 gene promoter polymorphisms on prostate cancer occurrence and prognosis in Han Chinese population”, vol. 12, pp. 820-829, 2013.
, Alexandrakis MG, Passam FH, Sfiridaki K, Moschandrea J, et al. (2004). Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk. Res. 28: 259-266.
http://dx.doi.org/10.1016/S0145-2126(03)00261-3
Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, et al. (2007). Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum. 56: 1787-1797.
http://dx.doi.org/10.1002/art.22705
PMid:17530707
Bushley AW, Ferrell R, McDuffie K, Terada KY, et al. (2004). Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol. Oncol. 95: 672-679.
http://dx.doi.org/10.1016/j.ygyno.2004.08.024
PMid:15581980
Charles AD (1999). Interleukin-18. Methods 19: 121-132.
http://dx.doi.org/10.1006/meth.1999.0837
PMid:10525448
Cho ML, Jung YO, Moon YM, Min SY, et al. (2006). Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol. Lett. 103: 159-166.
http://dx.doi.org/10.1016/j.imlet.2005.10.020
PMid:16368150
Desai KV, Michalowska AM, Kondaiah P, Ward JM, et al. (2004). Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate. Mol. Endocrinol. 18: 2895-2907.
http://dx.doi.org/10.1210/me.2004-0033
PMid:15358834
Dinarello CA (1999). IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J. Allergy Clin. Immunol. 103: 11-24.
http://dx.doi.org/10.1016/S0091-6749(99)70518-X
Eissa SA, Zaki SA, El-Maghraby SM and Kadry DY (2005). Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J. Egypt. Natl. Canc. Inst. 17: 51-55.
PMid:16353083
Figg WD, Franks ME, Venzon D, Duray P, et al. (2004). Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World J. Urol. 22: 425-430.
http://dx.doi.org/10.1007/s00345-004-0443-7
PMid:15592675
Fujita K, Ewing CM, Sokoll LJ, Elliott DJ, et al. (2008). Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. Prostate 68: 872-882.
http://dx.doi.org/10.1002/pros.20755
PMid:18361406 PMCid:2562260
Fujita K, Ewing CM, Isaacs WB and Pavlovich CP (2011). Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int. J. Cancer 129: 424-432.
http://dx.doi.org/10.1002/ijc.25705
PMid:20878981 PMCid:3040782
Giedraitis V, He B, Huang WX and Hillert J (2001). Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J. Neuroimmunol. 112: 146-152.
http://dx.doi.org/10.1016/S0165-5728(00)00407-0
Gillies SD, Young D, Lo KM and Roberts S (1993). Biological activity and in vivo clearance of antitumor antibody/ cytokine fusion proteins. Bioconjug. Chem. 4: 230-235.
http://dx.doi.org/10.1021/bc00021a008
PMid:8324014
Han MY, Zheng S, Yu JM, Peng JP, et al. (2004). Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity. J. Zhejiang Univ. Sci. 5: 472-476.
http://dx.doi.org/10.1631/jzus.2004.0472
PMid:14994440
Jung MK, Song HK, Kim KE, Hur DY, et al. (2006). IL-18 enhances the migration ability of murine melanoma cells through the generation of ROI and the MAPK pathway. Immunol. Lett. 107: 125-130.
http://dx.doi.org/10.1016/j.imlet.2006.08.004
PMid:17014914
Kalina U, Ballas K, Koyama N, Kauschat D, et al. (2000). Genomic organization and regulation of the human interleukin-18 gene. Scand. J. Immunol. 52: 525-530.
http://dx.doi.org/10.1046/j.1365-3083.2000.00836.x
PMid:11119255
Kim KE, Song H, Kim TS, Yoon D, et al. (2007). Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 26: 1468-1476.
http://dx.doi.org/10.1038/sj.onc.1209926
PMid:17001321
Lebel-Binay S, Thiounn N, De PG, Vieillefond A, et al. (2003). IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int. J. Cancer 106: 827-835.
http://dx.doi.org/10.1002/ijc.11285
PMid:12918059
Li Z, Zhang Z, He Z, Tang W, et al. (2009). A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 19: 519-523.
http://dx.doi.org/10.1038/cr.2009.33
PMid:19290020
Liu J, Liu J, Zhou Y, Li S, et al. (2011). Association between promoter variants of interleukin-18 and schizophrenia in a Han Chinese population. DNA Cell Biol. 30: 913-917.
http://dx.doi.org/10.1089/dna.2011.1221
PMid:21510800
Liu Y, Lin N, Huang L, Xu Q, et al. (2007). Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol. 26: 613-618.
http://dx.doi.org/10.1089/dna.2007.0600
PMid:17688413
Marshall DJ, Rudnick KA, McCarthy SG, Mateo LR, et al. (2006). Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Vaccine 24: 244-253.
http://dx.doi.org/10.1016/j.vaccine.2005.07.087
PMid:16135392
Merendino RA, Gangemi S, Ruello A, Bene A, et al. (2001). Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int. J. Biol. Markers 16: 126-129.
PMid:11471895
Okamura H, Tsutsi H, Komatsu T, Yutsudo M, et al. (1995). Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88-91.
http://dx.doi.org/10.1038/378088a0
PMid:7477296
Park H, Byun D, Kim TS, Kim YI, et al. (2001). Enhanced IL-18 expression in common skin tumors. Immunol. Lett. 79: 215-219.
http://dx.doi.org/10.1016/S0165-2478(01)00278-4
Pratesi C, Bortolin MT, Bidoli E, Tedeschi R, et al. (2006). Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol. Immunother. 55: 23-30.
http://dx.doi.org/10.1007/s00262-005-0688-z
PMid:16059673
Shi YY and He L (2005). SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15: 97-98.
http://dx.doi.org/10.1038/sj.cr.7290272
PMid:15740637
Stacey SN, Sulem P, Jonasdottir A, Masson G, et al. (2011). A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat. Genet. 43: 1098-1103.
http://dx.doi.org/10.1038/ng.926
PMid:21946351 PMCid:3263694
Takagawa T, Tamura K, Takeda N, Tomita T, et al. (2005). Association between IL-18 gene promoter polymorphisms and inflammatory bowel disease in a Japanese population. Inflamm. Bowel. Dis. 11: 1038-1043.
http://dx.doi.org/10.1097/01.MIB.0000182868.67025.b9
PMid:16306765
Tse BW, Russell PJ, Lochner M, Förster I, et al. (2011). IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS One 6: e24241.
http://dx.doi.org/10.1371/journal.pone.0024241
PMid:21935389 PMCid:3174151
Wang F, Zou YF, Feng XL, Su H, et al. (2011). CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies. Prostate 71: 1167-1177.
http://dx.doi.org/10.1002/pros.21332
Wentzensen N, Black A, Jacobs K, Yang HP, et al. (2011). Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the prostate, lung, colorectal, and ovarian cancer screening trial. PLoS One 6: e21731.
http://dx.doi.org/10.1371/journal.pone.0021731
PMid:21750727 PMCid:3131287
Xia D, Li F and Xiang J (2004). Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother. Radiopharm. 19: 322-330.
http://dx.doi.org/10.1089/1084978041424990
PMid:15285878
Ye ZB, Ma T, Li H, Jin XL, et al. (2007). Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J. Gastroenterol. 13: 1747-1751.
PMid:17461482
Yoon- DY, Cho YS, Park JW, Kim SH, et al. (2004). Up-regulation of reactive oxygen species (ROS) and resistance to Fas-mediated apoptosis in the C33A cervical cancer cell line transfected with IL-18 receptor. Clin. Chem. Lab. Med. 42: 499-506.
PMid:15202785
Zeegers MP, Khan HS, Schouten LJ, van Dijk BA, et al. (2011). Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant. Eur. J. Hum. Genet. 19: 118-120.
http://dx.doi.org/10.1038/ejhg.2010.133
PMid:20700145 PMCid:3039500
Zhou W, Chen Z, Hu W, Shen M, et al. (2011). Association of short tandem repeat polymorphism in the promoter of prostate cancer antigen 3 gene with the risk of prostate cancer. PLoS One 6: e20378.
http://dx.doi.org/10.1371/journal.pone.0020378
PMid:21655300 PMCid:3105025